MX384172B - Derivados de pirazol pirimidina y sus usos. - Google Patents

Derivados de pirazol pirimidina y sus usos.

Info

Publication number
MX384172B
MX384172B MX2018001395A MX2018001395A MX384172B MX 384172 B MX384172 B MX 384172B MX 2018001395 A MX2018001395 A MX 2018001395A MX 2018001395 A MX2018001395 A MX 2018001395A MX 384172 B MX384172 B MX 384172B
Authority
MX
Mexico
Prior art keywords
pyrimidine derivatives
methods
pyrazole pyrimidine
disorders
pyrazole
Prior art date
Application number
MX2018001395A
Other languages
English (en)
Spanish (es)
Other versions
MX2018001395A (es
Inventor
Dansu Li
Guy Brachya
Ido Burstain
Irit Snir-Alkalay
Joseph VACCA
Waleed Minzel
Yinon Ben NERIAH
Original Assignee
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd filed Critical Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Publication of MX2018001395A publication Critical patent/MX2018001395A/es
Publication of MX384172B publication Critical patent/MX384172B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2018001395A 2015-08-04 2016-08-04 Derivados de pirazol pirimidina y sus usos. MX384172B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200846P 2015-08-04 2015-08-04
US201562268750P 2015-12-17 2015-12-17
PCT/IL2016/050852 WO2017021969A1 (en) 2015-08-04 2016-08-04 Pyrazole pyrimidine derivative and uses thereof

Publications (2)

Publication Number Publication Date
MX2018001395A MX2018001395A (es) 2018-04-13
MX384172B true MX384172B (es) 2025-03-14

Family

ID=56738143

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001395A MX384172B (es) 2015-08-04 2016-08-04 Derivados de pirazol pirimidina y sus usos.

Country Status (23)

Country Link
US (4) US10376511B2 (https=)
EP (1) EP3331877B1 (https=)
JP (1) JP7083309B2 (https=)
KR (1) KR102698366B1 (https=)
CN (1) CN108137562B (https=)
AU (2) AU2016304464B2 (https=)
CA (1) CA2994644A1 (https=)
CY (1) CY1124898T1 (https=)
DK (1) DK3331877T3 (https=)
ES (1) ES2901349T3 (https=)
HR (1) HRP20211949T1 (https=)
HU (1) HUE057607T2 (https=)
IL (1) IL257282B (https=)
LT (1) LT3331877T (https=)
MX (1) MX384172B (https=)
PL (1) PL3331877T3 (https=)
PT (1) PT3331877T (https=)
RS (1) RS62728B1 (https=)
RU (1) RU2735522C2 (https=)
SI (1) SI3331877T1 (https=)
SM (1) SMT202100720T1 (https=)
WO (1) WO2017021969A1 (https=)
ZA (1) ZA201800671B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX384172B (es) * 2015-08-04 2025-03-14 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Derivados de pirazol pirimidina y sus usos.
TW201837027A (zh) 2017-02-01 2018-10-16 以色列商以色列耶路撒冷希伯來大學伊索研究發展有限公司 吡唑衍生物及其用途
TW202340194A (zh) 2017-02-16 2023-10-16 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
WO2019155468A1 (en) * 2018-02-08 2019-08-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
IL288547B2 (en) * 2019-06-03 2025-10-01 Biotheryx Inc Non-hygroscopic crystalline pyrazole compound salts, pharmaceutical preparations thereof and use thereof
WO2021000957A1 (zh) * 2019-07-04 2021-01-07 北京国鸿生物医药科技有限公司 一种杂环化合物、其药物组合物及用途
TW202115024A (zh) 2019-08-14 2021-04-16 美商英塞特公司 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
AU2020364007A1 (en) 2019-10-11 2022-04-28 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US20230047732A1 (en) * 2020-01-13 2023-02-16 Biotheryx, Inc. Pyrazolylpyrimidines and use thereof
WO2021155050A1 (en) * 2020-01-29 2021-08-05 Biotheryx, Inc. Kinase modulators, pharmaceutical compositions, and therapeutic applications
MX2022011901A (es) * 2020-03-26 2023-01-04 Janssen Pharmaceutica Nv Arilo piperidinas como moduladores de monoacilglicerol lipasa.
WO2022204220A1 (en) * 2021-03-24 2022-09-29 Biotheryx, Inc. Pyrazolylpyrimidines for treating malignant solid tumor
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11752151B2 (en) * 2021-07-12 2023-09-12 Buddhist Tzu Chi Medical Foundation Method for enhancing hair growth
US20230053307A1 (en) * 2021-07-19 2023-02-16 Buddhist Tzu Chi Medical Foundation Method for preventing or treating skin disorders and conditions
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2025199440A1 (en) * 2024-03-21 2025-09-25 Edgewood Oncology Methods of treating liposarcoma using a pyrazole compound
WO2025199434A1 (en) * 2024-03-21 2025-09-25 Edgewood Oncology Methods of treating breast cancer using a pyrazole compound

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111353A1 (en) 2000-12-05 2002-08-15 Mark Ledeboer Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
AU2002308748A1 (en) 2001-05-16 2002-11-25 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
US20090036448A1 (en) 2004-03-30 2009-02-05 Taisho Pharmecutical Co., Ltd. Pyrimidine derivatives and methods of treatment related to the use thereof
JP2007145819A (ja) 2005-10-28 2007-06-14 Tanabe Seiyaku Co Ltd 医薬組成物
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
JP2009538352A (ja) 2006-05-26 2009-11-05 アストラゼネカ アクチボラグ 細胞増殖を阻害するための薬剤としての2−カルボシクロアミノ−4−イミダゾリルピリミジン類
CA2707989A1 (en) 2007-12-07 2009-06-11 Novartis Ag Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
EP2776432B1 (en) 2011-11-04 2017-03-29 Jasco Pharmaceuticals LLC Aminopyrimidine kinase inhibitors
BR112016006319A2 (pt) * 2013-09-27 2017-08-01 Nimbus Iris Inc inibidores de irak e usos dos mesmos
US10047070B2 (en) 2013-10-18 2018-08-14 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
MX384172B (es) 2015-08-04 2025-03-14 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Derivados de pirazol pirimidina y sus usos.
TW201837027A (zh) * 2017-02-01 2018-10-16 以色列商以色列耶路撒冷希伯來大學伊索研究發展有限公司 吡唑衍生物及其用途
WO2019155468A1 (en) 2018-02-08 2019-08-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use

Also Published As

Publication number Publication date
US12514859B2 (en) 2026-01-06
AU2016304464A1 (en) 2018-02-22
HUE057607T2 (hu) 2022-06-28
HRP20211949T1 (hr) 2022-03-18
CN108137562A (zh) 2018-06-08
US11925641B2 (en) 2024-03-12
US20250049793A1 (en) 2025-02-13
EP3331877B1 (en) 2021-09-22
RS62728B1 (sr) 2022-01-31
US10376511B2 (en) 2019-08-13
NZ739511A (en) 2023-08-25
AU2016304464B2 (en) 2020-11-19
RU2018107668A (ru) 2019-09-05
RU2018107668A3 (https=) 2020-01-13
PT3331877T (pt) 2021-12-27
KR102698366B1 (ko) 2024-08-26
WO2017021969A1 (en) 2017-02-09
MX2018001395A (es) 2018-04-13
LT3331877T (lt) 2022-01-10
JP2018525441A (ja) 2018-09-06
US20210251992A1 (en) 2021-08-19
US20180214447A1 (en) 2018-08-02
ZA201800671B (en) 2020-05-27
SMT202100720T1 (it) 2022-01-10
CY1124898T1 (el) 2023-01-05
SI3331877T1 (sl) 2022-02-28
KR20180043794A (ko) 2018-04-30
AU2021200839A1 (en) 2021-03-04
US20190365759A1 (en) 2019-12-05
US10960003B2 (en) 2021-03-30
RU2735522C2 (ru) 2020-11-03
JP7083309B2 (ja) 2022-06-10
IL257282B (en) 2021-06-30
CA2994644A1 (en) 2017-02-09
CN108137562B (zh) 2021-11-30
PL3331877T3 (pl) 2022-01-31
HK1256535A1 (en) 2019-09-27
IL257282A (en) 2018-03-29
EP3331877A1 (en) 2018-06-13
DK3331877T3 (da) 2022-01-03
ES2901349T3 (es) 2022-03-22

Similar Documents

Publication Publication Date Title
MX384172B (es) Derivados de pirazol pirimidina y sus usos.
ZA202502750B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12016501107A1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
JOP20200228A1 (ar) تركيبات وطرق لخفض تعبير البروتين tau
PH12018500736A1 (en) Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
MX2019009812A (es) Proteinas quimericas basadas en tigit y light.
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX373341B (es) INHIBIDORES DE PROTEíNA CINASA 2 ACTIVADA POR PROTEíNA CINASA ACTIVADA POR MITóGENO (MK2) Y SUS USOS.
EA201990187A1 (ru) Антипролиферационные средства на основе пиримидина
IL255831A (en) Inhibitors of bruton's tyrosine kinase
MX2021015826A (es) Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
ECSP14013148A (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
EA032953B1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
BR112015021458A8 (pt) Processos e intermediários para preparar um inibidor de jak
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
ZA201805439B (en) Bruton's tyrosine kinase inhibitors
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
ZA201903694B (en) Inhibitors of bruton's tyrosine kinase
MX395032B (es) Ciertos inhibidores de la proteína quinasa.
WO2016154329A3 (en) P38 map kinase inhibitors for treating friedreich's ataxia
MX383460B (es) Derivados peptidicos novedosos y sus usos.
EA201791264A1 (ru) Соединения для лечения злокачественного новообразования
MX2016016371A (es) Nuevos compuestos.
HK1248601A1 (zh) 作為激酶抑制劑的嘧啶衍生物及其治療應用